What is it about?
This work shed new light on risk of type 1 diabetes in children seroconverting to single autoantibody in the pre-symptomatic period. Their risk in general is much less, but especially lower if they have low-risk HLA class II genotypes. While its known that children with multiple autoantibodies progress to developing type 1 diabetes in 5 to 15 years, this work has shown that having multiple autoantibodies at seroconversion, the earliest timepoint in development of autoimmunity, can reliably predict development of type 1 diabetes in up to 15 years in future.
Why is it important?
These findings have implications for prevention trial recruitment as well as clinical practice in counseling young children and families.
Read the Original
This page is a summary of: Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S., Diabetes Care, June 2021, American Diabetes Association, DOI: 10.2337/dc20-1836.
You can read the full text:
The following have contributed to this page